Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance
Company

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance

Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development
CompanyPolicy / Regulatory

Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development

Hainan Boao Research Hospital Secures Approval for China's First Medical-Food Import for Rare Metabolic Disorders
CompanyDrug

Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders

Sanofi's Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy
CompanyDrug

Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy

Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development
CompanyDeals

Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment
CompanyDrug

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388
CompanyDrug

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388

Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System
CompanyDeals

Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System

AstraZeneca's Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial
CompanyDrug

AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System
CompanyMedical Device

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals
Policy / Regulatory

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal
CompanyDeals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal